Dr. Hamidreza Montazeri Aliabadi

Dr. Hamidreza Montazeri Aliabadi

副教授
药学院
专业知识: Pharmaceutics; Targeted Delivery; RNA Interference; Cancer Biology; Signaling Pathways;
办公地点: Rinker Health Science Campus 211
电话: (714) 516-5492
学术著作:
数字共享
教育:
University of Tehran, Doctor of Pharmacy
阿尔伯塔大学博士.D.

传记

Dr. Montazeri joined CUSP on Aug. 1st, 2014 as an assistant professor of pharmaceutics. Dr. Montazeri graduated with a Pharm.D. degree from Tehran University in 1988. He worked in industrial pharmacy for more than ten years in different capacities (including 研究 and Development, 配方, 和质量控制), before continuing his studies.

He received his PhD in pharmaceutics (working on a project on targeted 交付 of small molecule drugs to solid tumors) from the 教师 of Pharmacy and Pharmaceutical Sciences, University of Alberta (亚利桑那大学), in 2007. During his graduate studies he was a teaching assistant for pharmaceutics courses, for which he was awarded Graduate Student Teaching Award in 2007 for excellence in teaching duties.

毕业后, he coordinated the pharmaceutics courses offered to undergraduate students of 亚利桑那大学 for two semesters, before a one year project as 研究 Associate working on 配方 and commercialization of a micro-emulsion based on ingredients used in traditional Chinese herbal medicine. He was then awarded a Postdoctoral fellowship by Alberta Heritage Foundation for Medical 研究 (now known as Alberta Innovates Health Solutions) on a project to design a polymeric carrier for siRNA 交付.

After completion of the fellowship in the Department of Chemical and Material Engineering, 亚利桑那大学, Dr. Montazeri wrote a research proposal (in collaboration) for studying signaling pathways to overcome resistance to chemotherapy in breast cancer, which was awarded a three year grant from Canadian Breast Cancer Foundation. His research interests are: (1) to design and characterize a safe and efficient multi-component 交付 system for targeted 交付 of small interfering RNAs; (2) to study the silencing mechanism and the factors affecting the silencing efficiency to optimize the RNA interference potential; and (3) to simultaneously silence a combination of proteins involved in signaling pathways responsible for enhanced proliferation and survival of cancer cells, and resistance towards chemotherapy. Dr. Montazeri has authored 28 peer-reviewed publications, 书中有两章, 以及 25 meeting abstracts.

研究兴趣

Dr. Montazeri’s research is focused on 交付 systems and RNA interference via small interfering RNAs (siRNAs). Regarding 交付 systems, recent efforts in Dr. Montazeri’s project have shown efficient silencing of specific proteins in different human breast cancer cell lines. Studies on developing new safe and efficient multicomponent lipid-based carriers generally known as stable nucleic acid lipid particles (SNALPs) are underway, which will be designed for active targeting of solid tumors. Protein silencing investigations in his lab are focused on understanding the interconnections among the signaling pathways involved in enhanced proliferation and survival, 以及, resistance to chemotherapeutic agents in cancer cells. Dr. Montazeri is specifically evaluating the potential of combinational silencing of selected proteins in an effort to effectively eradicate tumor growth.

Recent Creative, Scholarly Work and Publications

Dindyal Mandal, Sandeep罗汉, 穆罕默德·伊姆兰·萨吉德, Abdulelah Alhazza, Rakesh Kumar 女子* Keykavous帕兰刀*, Hamidreza Montazeri Aliabadi*. Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell lines. Pharmaceutics; 2023, 15: 666.
Hamidreza Montazeri Aliabadi*, Arthur Manda, Riya Sidgal, Co Chung. Targeting breast cancer: The Familiar, the Emerging and the Uncharted Territories. 生物分子. 2023; 13(9):1306.
Special Issue "Molecular Targets for Breast Cancer Therapy" in 生物分子 (Impact Factor: 5.5)
Emira Bousoik, 帕文Mahdipoor, Abdulelah Alhazza, Hamidreza Montazeri Aliabadi*. Combinational Silencing of Components Involved in JAK/STAT Signaling Pathway. European Journal of Pharmaceutical Sciences; 2022; 175: 106233.
Saghar Mozaffari, 大卫·萨利希, 帕文Mahdipoor, 理查德Beuttler, 拉克什女子*, Hamidreza Montazeri Aliabadi*, Keykavous帕兰刀*. Design and Application of Hybrid Cyclic-Linear Peptide -阿霉素 Conjugates as a Strategy to Overcome 阿霉素 抗性和毒性. European Journal of Medicinal Chemistry; 2021; 226:113836.
K. Zoghebi, Hamidreza Montazeri Aliabadi*, R.K. 女子* K. 帕兰刀*. [(WR) 8周ß]- 阿霉素 Conjugate: A Delivery System to Overcome Multi-Drug Resistance against 阿霉素. Cells; 2022; 11(2): 301.
D. Mandal E.H.M. 穆罕默德,年代. 罗汉,P. Mahdipoor D. Baradaran R. K. 女子,K. 帕兰刀,Hamidreza Montazeri Aliabadi*. Redox Responsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery. Molecular Pharmaceutics; 2022, 19(5): 1338-1355.
Uludag H*, Aliabadi HM, Gasiunas G. Editorial: Current approaches to CRISPR/Cas9 交付. 前沿Bioeng biotechnology. 2022年12月9日;10:1103007.
Ryley大厅, 阿卜杜勒阿齐兹Alasmari, Saghar Mozaffari, 帕文Mahdipoor Keykavous帕兰刀*, Hamidreza Montazeri Aliabadi*. Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System. Molecular Pharmaceutics; 2021; 18(3):986-1002.
Hamidreza Montazeri Aliabadi, J. Totonchy P. Mahdipoor K. 帕兰刀,H. Uludag. Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. Frontiers in Nanotechnology; 2021; 3:670543.
Saghar Mozaffari, 大卫·萨利希, 帕文Mahdipoor, 理查德Beuttler, 拉克什女子, Hamidreza Montazeri Aliabadi*, Keykavous帕兰刀. Design and Application of Hybrid Cyclic-Linear Peptide -阿霉素 Conjugates as a Strategy to Overcome 阿霉素 抗性和毒性. European Journal of Medicinal Chemistry; Under Review.
Hamidreza Montazeri Aliabadi*, Remant Bahadur K.C., E. Bousoik,. Barbarino B. Thapa, M. Coyle P. Mahdipoor H. Uludag *. A Systematic Comparison of Lipopolymers for siRNA Delivery to Breast Cancer Cell Lines: In vitro studies. Acta Biomaterialia, 2020; 102: 351-66.
H. Uludag * K. Parent, Hamidreza Montazeri Aliabadi, Azita Haddadi. Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology. 2020; 8:916
S. Mozaffari E. Bousoik F. Amirrad R. Lamboy, M. Coyle R. 大厅,. Alasmari P. Mahdipoor K. 帕兰刀,Hamidreza Montazeri Aliabadi*. Amphiphilic Peptides for Efficient siRNA Delivery. Polymers, 2019; 11(4): E703.
E. Bousoik R. Nabiee F. Amirrad,. 尼科尔斯,R. 威特,P. Mahdipoor Hamidreza Montazeri Aliabadi*. Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-targeted Drugs. Frontiers in Oncology, 2019; 9:1070.
J. V. Serna, Hamidreza Montazeri Aliabadi, X. 江,H. Uludag. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2018; 130:66-70.
M. Parmar D. N. M. Sundaram, Remant Bahadur KC, R. Maranchuk, Hamidreza Montazeri Aliabadi, J. C. 休,R. Lobenberg H. Uludag. Combinational siRNA 交付 using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia, 2018; 66:294-309.
N. S. El-Sayed, M. Sharma, Hamidreza Montazeri Aliabadi, M. G. El-Meligy,. K. El-Zaity Z. A. Nageib R. K. 女子. 合成, 描述, and in vitro cytotoxicity of fatty acyl-CGKRK-chitosan oligosaccharides conjugates for siRNA 交付. International Journal of Biological Macromolecules, 2018; 112: 694-702.
Al-Lawati H., Hamidreza Montazeri Aliabadi, Makhmalzadeh, B.S.L . Lavasanifar. Nanomedicine for Immunosuppressive Therapy: Achievements in Pre-Clinical and Clinical 研究. Expert Opinion on Drug Delivery. 2018, 15(4): 397-418.
E. Bousoik, Hamidreza Montazeri Aliabadi*. “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Frontiers in Oncology, 2018; 8:287.
R. Nabiee B. 杜布瓦,. 绿色,. 沙玛,年代. F. Wong, Hamidreza Montazeri Aliabadi*. In Vitro and Ex-vivo Evaluation of Topical Formulations designed to minimize transdermal absorption of Vitamin K1. PLOS ONE, 2018; 13(10): e0204531.
H. 做,米. 沙玛,N. Salem El-Sayed, P. Mahdipoor E. Bousoik K. 帕兰刀,Hamidreza Montazeri Aliabadi*. Difatty Acyl-Conjugated Linear and Cyclic peptides for siRNA Delivery. ACS Omega, 2017; 2(10):6939-57.
P. Zhu, Hamidreza Montazeri Aliabadi, H. Uludag J. 汉. Identification of Potential Drug Targets in Breast Cancer Signaling Pathway using Stochastic Logical Models. Scientific Reports, 2016; 6: 23078.
S.M. 加戈,一个. Falamarzian, Hamidreza Montazeri Aliabadi, M.R. Vakili H. Uludag,. Lavasanifar. Polymeric Micelles for siRNA Delivery to Breast Tumors: The effect of core/shell structure on in vitro and in vivo MCL-1 silencing in breast cancer. Nanomedicine, 2016; 11(17): 2319-39.
Hamidreza Montazeri Aliabadi*, P. Mahdipoor, M. Bisoffi H. Uludag. Changes in intracellular signaling after individual and combinational siRNA silencing in cancer cells. Molecular Pharmaceutics (Under Revision).
M. Parmar B. E. 阿尔蒂加·巴列斯特罗斯，T. Fu, R Bahadur KC, Hamidreza Montazeri Aliabadi, J. C. 休,R. Lobenberg H. Uludag. Multiple siRNA 交付 against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and non-malignant cells. Journal of Biomedical Materials 研究: Part A (Available onlibe; DOI: 10.1002 / jbm.a.35846).
M. 沙玛,N. S. El-Sayed H. 做,K. 帕兰刀,R. K. 女子, Hamidreza Montazeri Aliabadi*. Tumor-targeted 交付 of siRNA using fatty acyl-CGKRK peptide conjugates. Acta Biomaterialia (Under Revision).

教师 目录 by School or College